Japanese approval of Arzerra triggers milestone payment to Genmab

The regulatory body has approved Arzerra to treat patients with relapsed / refractory CD20-positive chronic lymphocytic leukemia (CLL).

Genmab chief executive officer Jan van de Winkel said, "We are pleased that patients in Japan will now have access to Arzerra. Japan is another important market for Arzerra and commercialization continues on track."

Genmab and GSK are jointly developing Ofatumumab under a co-development and commercialization agreement.

Human monoclonal antibody Ofatumumab targets an epitope on the CD20 molecule around parts of the small and large extracellular loops.